» Articles » PMID: 24280026

Monitoring Metabolic Responses to Chemotherapy in Single Cells and Tumors Using Nanostructure-initiator Mass Spectrometry (NIMS) Imaging

Overview
Journal Cancer Metab
Publisher Biomed Central
Specialty Oncology
Date 2013 Nov 28
PMID 24280026
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tissue imaging of treatment-induced metabolic changes is useful for optimizing cancer therapies, but commonly used methods require trade-offs between assay sensitivity and spatial resolution. Nanostructure-Initiator Mass Spectrometry imaging (NIMS) permits quantitative co-localization of drugs and treatment response biomarkers in cells and tissues with relatively high resolution. The present feasibility studies use NIMS to monitor phosphorylation of 3'-deoxy-3'-fluorothymidine (FLT) to FLT-MP in lymphoma cells and solid tumors as an indicator of drug exposure and pharmacodynamic responses.

Methods: NIMS analytical sensitivity and spatial resolution were examined in cultured Burkitt's lymphoma cells treated briefly with Rapamycin or FLT. Sample aliquots were dispersed on NIMS surfaces for single cell imaging and metabolic profiling, or extracted in parallel for LC-MS/MS analysis. Docetaxel-induced changes in FLT metabolism were also monitored in tissues and tissue extracts from mice bearing drug-sensitive tumor xenografts. To correct for variations in FLT disposition, the ratio of FLT-MP to FLT was used as a measure of TK1 thymidine kinase activity in NIMS images. TK1 and tumor-specific luciferase were measured in adjacent tissue sections using immuno-fluorescence microscopy.

Results: NIMS and LC-MS/MS yielded consistent results. FLT, FLT-MP, and Rapamycin were readily detected at the single cell level using NIMS. Rapid changes in endogenous metabolism were detected in drug-treated cells, and rapid accumulation of FLT-MP was seen in most, but not all imaged cells. FLT-MP accumulation in xenograft tumors was shown to be sensitive to Docetaxel treatment, and TK1 immunoreactivity co-localized with tumor-specific antigens in xenograft tumors, supporting a role for xenograft-derived TK1 activity in tumor FLT metabolism.

Conclusions: NIMS is suitable for monitoring drug exposure and metabolite biotransformation with essentially single cell resolution, and provides new spatial and functional dimensions to studies of cancer metabolism without the need for radiotracers or tissue extraction. These findings should prove useful for in vitro and pre-clinical studies of cancer metabolism, and aid the optimization of metabolism-based cancer therapies and diagnostics.

Citing Articles

Chemo-Selective Single-Cell Metabolomics Reveals the Spatiotemporal Behavior of Exogenous Pollutants During Xenopus Laevis Embryogenesis.

Li P, Gao S, Qu W, Li Y, Liu Z Adv Sci (Weinh). 2023; 11(9):e2305401.

PMID: 38115758 PMC: 10916618. DOI: 10.1002/advs.202305401.


Molecular imaging of bacterial biofilms-a systematic review.

van Hoogstraten S, Kuik C, Arts J, Cillero-Pastor B Crit Rev Microbiol. 2023; 50(6):971-992.

PMID: 37452571 PMC: 11523921. DOI: 10.1080/1040841X.2023.2223704.


Mass Spectrometry Imaging of Metabolites by Nanostructure Initiator Mass Spectrometry with Fluorinated Gold Nanoparticles.

Palermo A Methods Mol Biol. 2021; 2437:117-125.

PMID: 34902144 DOI: 10.1007/978-1-0716-2030-4_8.


The Application of Single-Cell Technologies in Cardiovascular Research.

Chen Y, Liu Y, Gao X Front Cell Dev Biol. 2021; 9:751371.

PMID: 34708045 PMC: 8542723. DOI: 10.3389/fcell.2021.751371.


Microfluidic Single-Cell Proteomics Assay Chip: Lung Cancer Cell Line Case Study.

Jung Y, Son M, Nam Y, Choi J, Heath J, Yang S Micromachines (Basel). 2021; 12(10).

PMID: 34683198 PMC: 8541572. DOI: 10.3390/mi12101147.


References
1.
Krohn K, Mankoff D, Eary J . Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol. 2001; 41(S7):96S-103S. View

2.
Morse D, Gray H, Payne C, Gillies R . Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther. 2005; 4(10):1495-504. DOI: 10.1158/1535-7163.MCT-05-0130. View

3.
Reyzer M, Caprioli R . MALDI-MS-based imaging of small molecules and proteins in tissues. Curr Opin Chem Biol. 2006; 11(1):29-35. DOI: 10.1016/j.cbpa.2006.11.035. View

4.
Smith C, Want E, OMaille G, Abagyan R, Siuzdak G . XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006; 78(3):779-87. DOI: 10.1021/ac051437y. View

5.
Hannigan B, Barnett Y, ARMSTRONG D, McKelvey-Martin V, McKenna P . Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biother. 1993; 8(3):189-97. DOI: 10.1089/cbr.1993.8.189. View